All patients
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L2 - all population, atezolizumab based treatment vs. docetaxel, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results OAK (all population), 2016 0.80 [0.70; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.79 [0.70 ; 0.89 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,512 moderate not evaluable progression or deaths (PFS)detailed results OAK (all population), 2016 0.96 [0.85; 1.08]
POPLAR, 2016 0.94 [0.72; 1.23]
0.96 [0.86 ; 1.07 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,512 moderate not evaluable objective responses (ORR)detailed results OAK (all population), 2016 1.19 [0.85; 1.67]
POPLAR, 2016 0.99 [0.52; 1.91]
1.15 [0.85 ; 1.55 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,512 moderate not evaluable AE (any grade)detailed results OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.69 [0.42 ; 1.13 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE (grade 3-4)detailed results OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.53 [0.43 ; 0.65 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to death (grade 5)detailed results OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
0.80 [0.40 ; 1.57 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.45 [0.24 ; 0.87 ] OAK (all population), 2016, POPLAR, 2016 2 66% 1,464 moderate not evaluable SAE (any grade)detailed results POPLAR, 2016 1.05 [0.64; 1.73]
1.05 [0.64 ; 1.73 ] POPLAR, 2016 1 0% 277 NA not evaluable SAE (grade 3-4)detailed results OAK (all population), 2016 1.03 [0.80; 1.31]
1.03 [0.80 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable TRAE (any grade)detailed results OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.29 [0.22 ; 0.38 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE (grade 3-4)detailed results OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.23 [0.18 ; 0.29 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE leading to death (grade 5)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.36 [0.05 ; 2.35 ] OAK (all population), 2016, POPLAR, 2016 2 0% 1,464 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results POPLAR, 2016 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] POPLAR, 2016 1 0% 277 NA not evaluable Alopecia AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Anaemia AE (grade 3-4)detailed results OAK (all population), 2016 0.39 [0.21; 0.73]
0.39 [0.21 ; 0.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Arthralgia AE (grade 3-4)detailed results OAK (all population), 2016 2.86 [0.30; 27.54]
2.86 [0.30 ; 27.54 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Asthenia AE (grade 3-4)detailed results OAK (all population), 2016 0.58 [0.24; 1.41]
0.58 [0.24 ; 1.41 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Back pain AE (grade 3-4)detailed results OAK (all population), 2016 1.67 [0.49; 5.73]
1.67 [0.49 ; 5.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Constipation AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Cough AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.17; 21.02]
1.90 [0.17 ; 21.02 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Decreased appetite AE (grade 3-4)detailed results OAK (all population), 2016 0.21 [0.04; 0.97]
0.21 [0.04 ; 0.97 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Diarrhoea AE (grade 3-4)detailed results OAK (all population), 2016 0.34 [0.11; 1.08]
0.34 [0.11 ; 1.08 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dysgeusia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.02; 47.91]
0.95 [0.02 ; 47.91 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dyspnoea AE (grade 3-4)detailed results OAK (all population), 2016 1.02 [0.49; 2.13]
1.02 [0.49 ; 2.13 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Fatigue AE (grade 3-4)detailed results OAK (all population), 2016 0.69 [0.37; 1.31]
0.69 [0.37 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Myalgia AE (grade 3-4)detailed results OAK (all population), 2016 0.24 [0.03; 2.12]
0.24 [0.03 ; 2.12 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Nausea AE (grade 3-4)detailed results OAK (all population), 2016 1.90 [0.35; 10.44]
1.90 [0.35 ; 10.44 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Neutropenia AE (grade 3-4)detailed results OAK (all population), 2016 0.03 [0.01; 0.11]
0.03 [0.01 ; 0.11 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results OAK (all population), 2016 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results OAK (all population), 2016 0.32 [0.03; 3.04]
0.32 [0.03 ; 3.04 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Pyrexia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.06; 15.21]
0.95 [0.06 ; 15.21 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Stomatitis AE (grade 3-4)detailed results OAK (all population), 2016 0.08 [0.01; 0.66]
0.08 [0.01 ; 0.66 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Vomiting AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.09; 2.59]
0.47 [0.09 ; 2.59 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 13:01 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 37
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866